Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H6O4 |
| Molecular Weight | 178.1415 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C2C=CC(=O)OC2=C1O
InChI
InChIKey=ATEFPOUAMCWAQS-UHFFFAOYSA-N
InChI=1S/C9H6O4/c10-6-3-1-5-2-4-7(11)13-9(5)8(6)12/h1-4,10,12H
Daphnetin (DAP), a natural coumarin derivative isolated from Chinese medicinal herbs, possesses abundant biological activities, such as anti-inflammatory, antioxidant, antimalarial and anti-arthritic. Experiments on mice have shown, that DAP exerts neuroprotective and anti-inflammatory effects, and the potential mechanism is involved the inhibition of TLR4/NF-κB mediated inflammatory signaling pathway. Besides, DAP, a multi-targeted medication, can have the application for the anti-angiogenesis and cancer therapy, through the inhibition of the IKKs/IκBα/NF-κB, Src/FAK/ERK1/2 and Akt signaling pathways. It is known, that protein kinases play key roles in the control of cell proliferation, differentiation, and metabolism. Daphnetin inhibits tyrosine-specific protein kinase, EGF receptor, serine/threonine-specific protein kinases, including cAMP-dependent protein kinase (PKA) and protein kinase C (PKC).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P00533|||Q9GZX1 Gene ID: 1956.0 Gene Symbol: EGFR Target Organism: Homo sapiens (Human) |
7.67 µM [IC50] | ||
Target ID: CHEMBL2094138 |
9.33 µM [IC50] | ||
Target ID: CHEMBL2093867 |
25.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Effect of daphnetin on the exo-erythrocytic stage of rodent malaria]. | 2001 |
|
| [Sensitization and crossreaction of simple coumarins]. | 2001 Jan |
|
| Antimicrobial evaluation of coumarins and flavonoids from the stems of Daphne gnidium L. | 2001 Jul |
|
| In vitro inhibitory effects of Daphne oleoides ssp. oleoides on inflammatory cytokines and activity-guided isolation of active constituents. | 2001 Mar 21 |
|
| In vitro antimalarial effect of daphnetin relating to its iron-chelating activity. | 2002 |
|
| In vitro cytotoxic potential and mechanism of action of selected coumarins, using human renal cell lines. | 2002 Sep 8 |
|
| [Effect of daphnetin on SOD activity and DNA synthesis of Plasmodium falciparum in vitro]. | 2003 |
|
| Daphnetin methylation by a novel O-methyltransferase is associated with cold acclimation and photosystem II excitation pressure in rye. | 2003 Feb 28 |
|
| Identification and characterisation of the chinese herb Langdu by LC-MS/MS analysis. | 2003 Jan-Feb |
|
| Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities. | 2004 |
|
| Comparative study on schizontocidal activity of recrystallized or crude daphnetin against malaria parasites. | 2004 Dec |
|
| [Additive therapeutic effect of a combination of artemether and daphnetin against Plasmodium berghei in mice]. | 2004 Jun |
|
| Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase. | 2004 May 1 |
|
| Binding of the bioactive component daphnetin to human serum albumin demonstrated using tryptophan fluorescence quenching. | 2004 May 17 |
|
| Spectrofluorimetric study of the binding of daphnetin to bovine serum albumin. | 2004 May 28 |
|
| Iron chelator daphnetin against Pneumocystis carinii in vitro. | 2004 Nov |
|
| Solid-phase extraction of esculetin from the ash bark of Chinese traditional medicine by using molecularly imprinted polymers. | 2005 Jan 7 |
|
| [In vitro effect of daphnetin on cytochrome C oxidase and ribonucleotide reductase of plasmodium falciparum]. | 2006 Jun |
|
| Antifungal and antibacterial activities of Mexican tarragon (Tagetes lucida). | 2006 May 17 |
|
| In vitro potentiation of antimalarial activities by daphnetin derivatives against Plasmodium falciparum. | 2006 Oct |
|
| Multi-substrate flavonol O-glucosyltransferases from strawberry (Fragaria x ananassa) achene and receptacle. | 2008 |
|
| Recent advances in the compound-oriented and pattern-oriented approaches to the quality control of herbal medicines. | 2008 Aug 4 |
|
| Structural insights into hydroxycoumarin-induced apoptosis in U-937 cells. | 2008 Mar 1 |
|
| Therapeutic effects of daphnetin on adjuvant-induced arthritic rats. | 2008 Nov 20 |
|
| [Intestinal absorption of daphnetin by rats single pass perfusion in situ]. | 2009 Aug |
|
| Effect of chemical enhancers on percutaneous absorption of daphnetin in isopropyl myristate vehicle across rat skin in vitro. | 2009 May |
|
| Potential utility of daphnetin as a novel treatment for pemphigus vulgaris. | 2010 Aug |
|
| Traditional herbal medicine in far-west Nepal: a pharmacological appraisal. | 2010 Dec 13 |
|
| Antioxidant activities of coumarins from Korean medicinal plants and their structure-activity relationships. | 2010 Jan |
|
| Identification and characterization of human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of daphnetin. | 2010 Jun |
|
| Novel insights into the mechanism of decreased expression of type X collagen in human mesenchymal stem cells from patients with osteoarthritis cultured on nitrogen-rich plasma polymers: implication of cyclooxygenase-1. | 2010 Sep 1 |
Sample Use Guides
in rats: six sprague-dawley rats received intragastric administration of D. giraldii extract (daphnetin, daphnoretin and daphneticin were 88.40, 3.24 and 4.28 mg•kg⁻¹, respectively).
Route of Administration:
Intragastric
To test the in vitro effect of daphnetin on cytochrome C oxidase (COX) and ribonucleotide reductase (RNR) activity of Plasmodium falciparum. The parasites synchronized with sorbitol in vitro was treated by daphnetin and daphnetin-Fe complex. The inhibition level of the COX activity by daphnetin after being treated for 2, 4, 8 and 12 h were 0.6%, 73% and 80% respectively and the inhibition level by daphnetin at different concentrations (0.1, 1, 100 and 1 mmol/L) for 6h was 3%, 31%, 53% and 84%, respectively.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5280569
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
633563
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
m4087
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID00197560
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
17313
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
C039952
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
207-632-8
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
486-35-1
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY | |||
|
XC84571RD2
Created by
admin on Fri Dec 15 18:50:33 GMT 2023 , Edited by admin on Fri Dec 15 18:50:33 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
